CORRECTED: Pfizer Takes Fight Over $142M Neurontin Verdict To 1st Circ.

Law360, New York (July 25, 2012, 6:20 PM EDT) -- Pfizer Inc. is challenging a $142 million jury award for HMO operator Kaiser Foundation Health Plan Inc. in multidistrict litigation over off-label marketing of pain drug Neurontin, telling the First Circuit that Kaiser hadn’t proven it had suffered an injury.

The drugmaker filed a brief July 19 with the appeals court on behalf of itself and subsidiary Warner-Lambert Co. LLC, the developer of Neurontin, saying U.S. District Judge Patti B. Saris had made several substantial errors in the case, which accuses Pfizer of violating the Racketeer...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.